A Phase 3, Randomized, Observer-Blind, Active-Controlled Study to Compare the Immunogenicity against COVID-19, of S-268019 to the ChAdOx1 nCoV-19 vaccine (COVID-19)

agata Tsutae0 个研究点目标入组 1,000 人开始时间: 2022年1月13日最近更新: 2023年10月17日

研究概览

暂无简介。

•Participant must be >= 18 years of age, at the time of signing the informed consent form (ICF).
•Male and female
•Capable of giving signed ICF which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

•Current or history of a laboratory-confirmed diagnosis of SARS-CoV-2 infection or COVID-19.
•Unstable current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disease that, in the opinion of the investigator or subinvestigator, would constitute a safety concern or confound data interpretation.
•Immunosuppression (immunodeficiency, acquired immunodeficiency syndrome [AIDS], use of systemic steroids, use of immunosuppressants within the past 6 months prior to the first dose of study intervention, treatment for malignant tumors, other immunosuppressive therapy).
•Individuals considered to have hypersensitivity to any of the study interventions,or components thereof, or drug or other allergy that, in the opinion of the investigator or subinvestigator, contraindicates participation in the study (except for pollinosis and atopic dermatitis).
•Participant has a contraindication to intramuscular(IM) injections or blood draws.

发起方

agata Tsutae